<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04901728</url>
  </required_header>
  <id_info>
    <org_study_id>PEDALstudy</org_study_id>
    <nct_id>NCT04901728</nct_id>
  </id_info>
  <brief_title>Patients' Experiences and Perceptions of 3TC/DTG Dual Therapy (the PEDAL Study)</brief_title>
  <acronym>PEDAL</acronym>
  <official_title>Lamivudine (3TC) Plus Dolutegravir (DTG) Dual Therapy: a Study on Patients' Experiences and Perceptions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sussex</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Brighton and Sussex University Hospitals NHS Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Sussex</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Improvements in health care and antiretroviral treatments have made it possible to turn HIV&#xD;
      into a chronic disease leading to longer life expectancies and better quality of life among&#xD;
      patients. Dual-drug combinations offer the advantage of a reduced exposure to antiretroviral&#xD;
      agents, therefore leading to potential reductions in drug-associated side effects in the&#xD;
      long-term. In light of this context, the primary aim of this qualitative study is to&#xD;
      investigate patients' perceptions and experiences on the safety, effectiveness, tolerability,&#xD;
      and unmet needs of the dolutegravir/lamivudine two-drug regimen. The secondary objective is&#xD;
      to conduct a comparative analysis between patients on dolutegravir/lamivudine and patients on&#xD;
      other two-drug and three-drug combinations. Lastly, the study aims to provide recommendations&#xD;
      that improve doctor-patient communication, knowledge and understanding of the treatment plan,&#xD;
      and additional care that ought to be considered in patient-centred, holistic care plans.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators propose a three-phase comparative study with a control population (i.e.,&#xD;
      people living with HIV on other dual therapy regimens and triple ART) and the target&#xD;
      population (i.e., people living with HIV on dual DTG/3TC regimen). The control population&#xD;
      will include a group on dual regimens other than DTG/3TC and a group on triple therapy. In&#xD;
      the control group of patients receiving dual therapies, the investigators will include&#xD;
      patients (i) on Juluca (DTG/rilpivirine[RPV]), (ii) on boosted darunavir plus lamivudine&#xD;
      (DRV/r or DRV/c + 3TC), and (iii) on boosted darunavir plus raltegravir (DRV/r or DRV/c +&#xD;
      RAL). The target population will include patients on DTG/3TC. The addition of the control&#xD;
      group of patients on other dual therapies will allow the investigators to tease out the&#xD;
      particular characteristics of the dual DTG/3TC beyond the mere reduction of molecules&#xD;
      employed for the treatment.&#xD;
&#xD;
      The investigators suggest that a comparative study including the target and control&#xD;
      populations will allow to better understand patient perceptions and needs as related to the&#xD;
      variables of (i) safety, (ii) effectiveness, (iii) tolerability, and (iv) unmet needs. This&#xD;
      is because DTG/3TC will not be experienced and perceived in isolation from the patients'&#xD;
      previous drug regimens or from other patients on different drug regimens. When a participant&#xD;
      on DTG/3TC describes their experiences and perceptions, they will be making a comparison to a&#xD;
      'time before' or to 'an other'. For example, the investigators anticipate patients to&#xD;
      describe current experiences of DTG/3TC effectiveness in comparison to a time they were on&#xD;
      another drug regimen or in comparison to a friend/known person on another drug regimen (e.g.&#xD;
      'DTG/3TC is more effective than my previous treatment' or 'DTG/3TC seems to be less tolerable&#xD;
      because my friend is on a different regimen and has fewer side-effects'). This supports the&#xD;
      need to explore other drug regimens through a control group so that comparisons that arise in&#xD;
      the data will have a reference point rooted in the data. In short, if a patient says 'DTG/3TC&#xD;
      is safer than my previous treatment' the investigators can understand not only experiences on&#xD;
      DTG/3TC, but also how it compares to other treatments.&#xD;
&#xD;
      Additionally, the subjective nature of these variables means that each person will have a&#xD;
      different understanding, meaning, perception, and experience of the study variables. ViiV&#xD;
      Healthcare, the researchers, and health care providers will have one, or more, ways of&#xD;
      defining the variables, but there is added value in exploring what they mean to patients. By&#xD;
      widening our participant population to not just include the target population, but to also&#xD;
      include the control groups the investigators will gain a more in-depth understanding of what&#xD;
      these variables mean to patients. This will ensure conceptual and operational alignment of&#xD;
      the variables between patients and researchers.&#xD;
&#xD;
      This study's 'phases' refer to the order in which specific methods will be deployed and&#xD;
      findings preliminarily analysed. In Phase I the investigators will deploy Cultural Domain&#xD;
      Analysis (CDA), a type of structured interview aimed at understanding how people in a group&#xD;
      think about lists of things that somehow go together. CDA will help the investigators to&#xD;
      better understand patient unmet needs. After data collection, the investigators will conduct&#xD;
      a preliminary analysis to refine and improve our Focus Group Discussion (FGD) questions and&#xD;
      approach. In Phase II the investigators will conduct FGDs to gain a deeper knowledge of&#xD;
      patient unmet needs and to begin exploring the variables safety, efficacy, and tolerability.&#xD;
      The investigators will conduct a preliminary analysis of the FGDs to refine the questions and&#xD;
      approach the subsequent In-Depth Interviews (IDI). In Phase III the investigators will&#xD;
      conduct IDIs to gain expert knowledge and understanding of the variables safety, efficacy,&#xD;
      and tolerability. The investigators will conduct a preliminary analysis of the data. Finally,&#xD;
      the investigators will analyse all data sets, prepare journal articles, conference papers,&#xD;
      and share findings through public engagement with both the Brighton and Sussex Medical School&#xD;
      and the Sussex Beacon.&#xD;
&#xD;
      The investigators will ask the control population to draw on their knowledge of the DTG/3TC&#xD;
      regimen, and the target population to share their experiences on DTG/3TC; both in relation to&#xD;
      the above-mentioned variables. By asking the control population about the DTG/3TC regimen (as&#xD;
      opposed to their current care plan) the investigators will illuminate potential gaps in&#xD;
      knowledge and understanding about the DTG/3TC regimen, as well as potential misconceptions&#xD;
      among HIV patients in treatment about the 2-drug therapy.&#xD;
&#xD;
      The investigators will also ask the control population about their current dual and triple&#xD;
      therapy regimens and the target population about their previous experiences on triple therapy&#xD;
      or alternative dual therapy combinations before switching to the DTG/3TC regimen; both in&#xD;
      relation to the above-mentioned variables. By including exploration of different treatments,&#xD;
      the investigators will gain an understanding of whether patients perceive the new regimen to&#xD;
      be safer, effective, and more tolerable, as well as if they feel previously unmet needs are&#xD;
      now met on the new treatment plan. The investigators can also gauge the potential interest&#xD;
      and/or concern/worry/fear that patients on triple and alternative dual therapies may feel&#xD;
      about the future direction of HIV treatment.&#xD;
&#xD;
      This data will enable the investigators to provide recommendations for improved&#xD;
      doctor-patient communication and health education about the 2-drug and DTG/3TC regimen. It&#xD;
      may also allow identifying psycho-social concerns that support teams should be aware of or&#xD;
      anticipate as patient treatment plans change.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2021</start_date>
  <completion_date type="Anticipated">September 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Cultural Domain Analysis</measure>
    <time_frame>June to September 2021 (up to a month after the study starts)</time_frame>
    <description>Question to evaluate patients' unmet needs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Focus Group Discussions</measure>
    <time_frame>Following completion of cultural domain analysis (October to November 2021, five months after the study starts)</time_frame>
    <description>To investigate patients' perceptions and experiences on the safety, effectiveness, tolerability, and unmet needs of the DTG/3TC 2-drug regimen</description>
  </primary_outcome>
  <primary_outcome>
    <measure>In-depth interviews</measure>
    <time_frame>Two months after completing focus group discussions (January to March 2022, eight months after the study starts)</time_frame>
    <description>To investigate patients' perceptions and experiences on the safety, effectiveness, tolerability, and unmet needs of the DTG/3TC 2-drug regimen</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">120</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Target Population</arm_group_label>
    <description>People living with HIV and following a DTG/3TC drug regimen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group on Dual Regimens</arm_group_label>
    <description>The first control population will include a group on dual regimens other than DTG/3TC and a group on triple therapy. In the control group of patients receiving dual therapies, we will include patients (i) on Juluca (DTG/rilpivirine[RPV]), (ii) on boosted darunavir plus lamivudine (DRV/r or DRV/c + 3TC), and (iii) on boosted darunavir plus raltegravir (DRV/r or DRV/c + RAL).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group on Triple Regimens</arm_group_label>
    <description>The second control population will include a group on triple regimens including: 2 NRTIs + 1 NNRTI; 2 NRTIs + 1 INSTI, and 2 NRTIs + 1 PI/b.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Cultural Domain Analysis</intervention_name>
    <description>80 and up to a maximum of 120 participants</description>
    <arm_group_label>Control Group on Dual Regimens</arm_group_label>
    <arm_group_label>Control Group on Triple Regimens</arm_group_label>
    <arm_group_label>Target Population</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Focus Group Discussion</intervention_name>
    <description>At least 18 and up to a maximum of 60 participants</description>
    <arm_group_label>Control Group on Dual Regimens</arm_group_label>
    <arm_group_label>Control Group on Triple Regimens</arm_group_label>
    <arm_group_label>Target Population</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>In-depth interview</intervention_name>
    <description>At least 18 and up to a maximum of 36 participants</description>
    <arm_group_label>Control Group on Dual Regimens</arm_group_label>
    <arm_group_label>Control Group on Triple Regimens</arm_group_label>
    <arm_group_label>Target Population</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patient participants will consist of 18+ people living with HIV in the Brighton and Hove&#xD;
        area, and receiving HIV care at the HIV Department of the Brighton and Sussex University&#xD;
        Hospital (Lawson Unit/Elton John Centre).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults (aged 18 years old or older)&#xD;
&#xD;
          -  Able to consent&#xD;
&#xD;
          -  Receive HIV care at the HIV Department of the Brighton and Sussex University Hospital&#xD;
             (Lawson Unit/Elton John Centre)&#xD;
&#xD;
          -  All genders, sexual orientations, and socio-economic groups are eligible for&#xD;
             participation&#xD;
&#xD;
          -  On one of the following therapies&#xD;
&#xD;
          -  Control population&#xD;
&#xD;
               -  Juluca (DTG/rilpivirine[RPV])&#xD;
&#xD;
               -  Boosted darunavir plus lamivudine (DRV/r or DRV/c + 3TC)&#xD;
&#xD;
               -  Boosted darunavir plus raltegravir (DRV/r or DRV/c + RAL)&#xD;
&#xD;
               -  A triple regimen (2 nucleos(t)ide reverse transcriptase inhibitors [NRTIs] + 1&#xD;
                  InSTI; 2 NRTIs + 1 non-nucleoside reverse transcriptase inhibitor [NNRTI]; 2&#xD;
                  NRTIs + boosted protease inhibitor [PI/b])&#xD;
&#xD;
          -  Target population&#xD;
&#xD;
               -  DTG/3TC&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients taking off-label drug combinations due to complex HIV resistance patterns.&#xD;
&#xD;
          -  ART na√Øve or individuals declining ART will be excluded.&#xD;
&#xD;
          -  Patients without access to the technology to participate in the online study will be&#xD;
             given the option to participate in person (following COVID-19 guidance), and if this&#xD;
             is not possible they will be excluded.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giovanni Villa</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brighton &amp; Sussex Medical School</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Giovanni Villa</last_name>
    <phone>+447760685755</phone>
    <email>G.Villa@bsms.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Diego Garcia Rodriguez</last_name>
    <phone>+447923232006</phone>
    <email>d.garcia@bsms.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Royal Sussex County Hospital, Brighton, UK</name>
      <address>
        <city>Brighton</city>
        <zip>BN2 5BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanda Clarke</last_name>
      <email>amanda.clarke16@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Caroline Ackley</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 18, 2021</study_first_submitted>
  <study_first_submitted_qc>May 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 25, 2021</study_first_posted>
  <last_update_submitted>July 30, 2021</last_update_submitted>
  <last_update_submitted_qc>July 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>3TC/DTG</keyword>
  <keyword>dual therapy</keyword>
  <keyword>qualitative</keyword>
  <keyword>cultural domain analysis</keyword>
  <keyword>dual regimen</keyword>
  <keyword>triple regimen</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 1, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/28/NCT04901728/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

